Literature DB >> 27354148

MicroRNA-223 affects IL-6 secretion in mast cells via the IGF1R/PI3K signaling pathway.

Qianyuan Yang1, Hong Xu1, Jin Yang2, Yao Zhou1, Deyu Zhao1, Feng Liu1.   

Abstract

In this study, we aimed to assess the effects of microRNA-223 (miR-223) on interleukin-6 (IL-6) secretion in mast cells and determine the underlying molecular mechanisms. Mast cells (P815) were transfected with miR-223 lentiviral vector and miR-223 inhibitor. miR-223 expression was then evaluated using reverse transcription-quantitative PCR (RT-qPCR). IL-6 levels in the supernatant were analyzed using enzyme-linked immunosorbent assay. The signaling pathways in mast cells with downregulated miR-223 were initially evaluated by gene chip. Downregulation of miR-223 and its target gene was tested using a luciferase reporter assay. The expression of phosphate-AKT (p-AKT) and its target protein insulin-like growth factor-1 receptor (IGF1R) was assessed by western blot analysis. Phosphatidylinositol 3-kinase (PI3K)-inhibitor (LY294002) and insulin-like growth factor-1 (IGF1) were used to determine the effect of miR-223 on IL-6 secretion in mast cells. The results showed that microRNA-223 reduced IL-6 concentration in the mast cells. The gene chip results predicted an induction of the PI3K-AKT signaling pathway in the mast cells. Luciferase reporter assay confirmed IGF1R gene to be a target of miR-223. The p-AKT and IGF1R levels increased following miR-223 downregulation in mast cells. In addition, the specific PI3K‑inhibitor LY294002 decreased IL-6 secretion. Incubation with IGF1 resulted in the induction of IL-6 secretion in miR-223‑expressing mast cells. In conclusion, it was shown that miR-223 reduces IL-6 secretion in mast cells by inhibiting the IGF1R/PI3K signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27354148     DOI: 10.3892/ijmm.2016.2649

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

1.  Epithelial cells expressed IL-33 to promote degranulation of mast cells through inhibition on ST2/PI3K/mTOR-mediated autophagy in allergic rhinitis.

Authors:  Jia-Bin Nian; Min Zeng; Jing Zheng; Lian-Ya Zeng; Zhi Fu; Qiu-Ju Huang; Xin Wei
Journal:  Cell Cycle       Date:  2020-04-16       Impact factor: 4.534

2.  Inhibition of airway inflammation in a cockroach allergen model of asthma by agonists of miRNA-33b.

Authors:  Ruichao Niu; Xuping Xiao; Bin Liu; Yunqiu Li; Yu Zhong; Lijuan Ma
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

3.  In vivo targeting of miR-223 in experimental eosinophilic oesophagitis.

Authors:  Adam M Collison; Leon A Sokulsky; Scott Nightingale; Elizabeth Percival; Anna LeFevre; Joseph Meredith; Sybille Krauss; Paul S Foster; Joerg Mattes
Journal:  Clin Transl Immunology       Date:  2020-11-23

Review 4.  Role of Exosomal miR-223 in Chronic Skeletal Muscle Inflammation.

Authors:  Yuan Tian; Tie-Shan Wang; He Bu; Guo Shao; Wei Zhang; Li Zhang
Journal:  Orthop Surg       Date:  2022-03-16       Impact factor: 2.071

Review 5.  MicroRNA Involvement in Allergic and Non-Allergic Mast Cell Activation.

Authors:  Irit Shefler; Pazit Salamon; Yoseph A Mekori
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

Review 6.  Koebner phenomenon leading to the formation of new psoriatic lesions: evidences and mechanisms.

Authors:  Yong-Zhi Ji; Shi-Rui Liu
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

Review 7.  Recent advances in mast cell activation and regulation.

Authors:  Hwan Soo Kim; Yu Kawakami; Kazumi Kasakura; Toshiaki Kawakami
Journal:  F1000Res       Date:  2020-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.